[go: up one dir, main page]

WO2009080764A3 - Oral or nasal administration of compounds comprising amino acid sequences - Google Patents

Oral or nasal administration of compounds comprising amino acid sequences Download PDF

Info

Publication number
WO2009080764A3
WO2009080764A3 PCT/EP2008/068053 EP2008068053W WO2009080764A3 WO 2009080764 A3 WO2009080764 A3 WO 2009080764A3 EP 2008068053 W EP2008068053 W EP 2008068053W WO 2009080764 A3 WO2009080764 A3 WO 2009080764A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
oral
nasal administration
amino acid
acid sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/068053
Other languages
French (fr)
Other versions
WO2009080764A2 (en
Inventor
Hendricus Renerus Jacobus Mattheus Hoogenboom
Johannes Joseph Wilhelmus De Haard
Maria Gonzalez
Peter Vanlandschoot
Jan Terje Andersen
Gestuur Vidarsson
Edward Dolk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABYLNX NV
Original Assignee
ABYLNX NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ABYLNX NV filed Critical ABYLNX NV
Publication of WO2009080764A2 publication Critical patent/WO2009080764A2/en
Publication of WO2009080764A3 publication Critical patent/WO2009080764A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compounds comprising amino acid sequences such as single variable domains for oral or nasal administration and pharmaceutical compositions comprising said compounds. More particularly, the invention relates to compounds wherein binding to at least one of the antigens or epitopes selected from the group of epithelial transporters act to increase the bioavailability of the compound in vivo. The present invention furthermore provides various additional methods to enhance bioavailability of said compounds of the invention when using oral or nasal administration.
PCT/EP2008/068053 2007-12-20 2008-12-19 Oral or nasal administration of compounds comprising amino acid sequences Ceased WO2009080764A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1532007P 2007-12-20 2007-12-20
US61/015,320 2007-12-20
US5389208P 2008-05-16 2008-05-16
US61/053,892 2008-05-16

Publications (2)

Publication Number Publication Date
WO2009080764A2 WO2009080764A2 (en) 2009-07-02
WO2009080764A3 true WO2009080764A3 (en) 2010-06-03

Family

ID=40668459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/068053 Ceased WO2009080764A2 (en) 2007-12-20 2008-12-19 Oral or nasal administration of compounds comprising amino acid sequences

Country Status (1)

Country Link
WO (1) WO2009080764A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
PT2387583T (en) * 2009-01-14 2018-12-24 Ablynx Nv PULMONARY ADMINISTRATION OF SINGLE IMMUNOGLOBULIN VARIABLE AREAS AND CONSTRUCTIONS
EP2275442A1 (en) * 2009-07-06 2011-01-19 Ludwig-Maximilians-Universität München Detection and vizualization of the cell cycle in living cells
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) * 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CA2975710C (en) 2015-02-09 2023-08-08 Entera Bio Ltd. Treatment of osteoporosis
BR112019003136A2 (en) 2016-08-17 2019-05-21 Entera Bio Ltd multi-unit dosage form of pharmaceutical composition, unit dosage form of pharmaceutical composition, multi-unit / unit dosage form, kit and method of treating a condition treatable by oral administration of a therapeutically active agent
BR112022001352A2 (en) * 2019-08-02 2022-06-07 Janssen Biotech Inc Materials and methods for multidirectional biotransport
BR112022003735A2 (en) * 2019-08-29 2022-06-21 Nat Institute For Biotechnology In The Negev Ltd Single domain antibody to target prostate-specific membrane antigen (psma)
US12134658B2 (en) 2020-08-03 2024-11-05 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
TW202229335A (en) * 2020-10-12 2022-08-01 美商健生生物科技公司 Biosynthetic materials and methods for multidirectional biotransportation
IL317042A (en) 2022-05-30 2025-01-01 Hanall Biopharma Co Ltd Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024107885A1 (en) * 2022-11-15 2024-05-23 Vanderbilt University Nanobody-drug conjugates and methods of preparing thereof
AR131494A1 (en) 2022-12-23 2025-03-26 Ablynx Nv PROTEIN-BASED CONJUGATION VEHICLES
CN120712282A (en) 2023-02-17 2025-09-26 阿布林克斯有限公司 Polypeptides that bind neonatal FC receptors
US20250034260A1 (en) * 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005073383A2 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
US20070020192A1 (en) * 1995-01-17 2007-01-25 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20070087001A1 (en) * 2005-10-19 2007-04-19 Center For Molecular Medicine And Immunology Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007087289A2 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2008074868A1 (en) * 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020192A1 (en) * 1995-01-17 2007-01-25 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005073383A2 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
US20050186662A1 (en) * 2004-01-28 2005-08-25 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
US20070087001A1 (en) * 2005-10-19 2007-04-19 Center For Molecular Medicine And Immunology Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007087289A2 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2008074868A1 (en) * 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE CHANG HOON ET AL: "Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, ACADEMIC PRESS, US, vol. 46, no. 3-4, 1 April 2007 (2007-04-01), pages 211 - 217, XP009105401, ISSN: 0885-4513 *

Also Published As

Publication number Publication date
WO2009080764A2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2009080764A3 (en) Oral or nasal administration of compounds comprising amino acid sequences
WO2009034119A8 (en) Improved derivatives of amylin
EP3210625A3 (en) Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2010127856A8 (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2012019165A3 (en) Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2006028936A3 (en) Heteromultimeric molecules
WO2010139808A3 (en) Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2008013838A3 (en) Pyridizinone derivatives
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2009067686A3 (en) Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2008017381A8 (en) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
TW200630336A (en) Novel compounds
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
TW200621690A (en) Novel compounds
TW200621313A (en) Pharmaceutical compositions
WO2007052023A3 (en) Novel compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08863859

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08863859

Country of ref document: EP

Kind code of ref document: A2